• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Agios Pharmaceuticals Inc.

    3/5/25 5:27:09 PM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AGIO alert in real time by email
    S-8 1 d908936ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on March 5, 2025

    Registration No. 333-

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Agios Pharmaceuticals, Inc.

    (Exact Name of Registrant as Specified in Its Charter)

     

     

     

    Delaware   26-0662915

    (State or Other Jurisdiction of

    Incorporation or Organization)

     

    (I.R.S. Employer

    Identification No.)

    88 Sidney Street

    Cambridge, MA

      02139
    (Address of Principal Executive Offices)   (Zip Code)

    Inducement Stock Option Award (March 2025)

    Inducement Restricted Stock Unit Award (March 2025)

    Inducement Performance Stock Unit Award (March 2025)

    (Full Title of the Plan)

    Brian Goff

    Chief Executive Officer

    Agios Pharmaceuticals, Inc.

    88 Sidney Street

    Cambridge, MA 02139

    (Name and Address of Agent For Service)

    (617) 649-8600

    (Telephone Number, Including Area Code, of Agent For Service)

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    Item 1. Plan Information.

    The information required by Item 1 is omitted from this registration statement and included in documents sent or given to participants in the plans covered by this registration statement pursuant to Rule 428(b)(1) of the Securities Act of 1933, as amended (the “Securities Act”).

    Item 2. Registrant Information and Employee Plan Annual Information.

    The written statement required by Item 2 is omitted from this registration statement and included in documents sent or given to participants in the plans covered by this registration statement pursuant to Rule 428(b)(1) of the Securities Act.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The registrant is subject to the informational and reporting requirements of Sections 13(a), 14, and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and in accordance therewith files reports, proxy statements and other information with the Securities and Exchange Commission (the “Commission”). The following documents, which are on file with the Commission, are incorporated in this registration statement by reference:

    (a) the registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 as filed with the Commission on February 13, 2025;

    (b) the information included in our definitive proxy statement on Schedule 14A for the 2024 Annual Meeting of Stockholders, as filed with the Commission on April 26, 2024, to the extent incorporated by reference into Part III of the Annual Report on Form 10-K for the fiscal year ended December 31, 2023;

    (c) the registrant’s Current Report on Form 8-K as filed with the Commission on February 13, 2025; and

    (d) the description of the registrant’s common stock contained in the registrant’s registration statement on Form 8-A filed under the Exchange Act on July  19, 2013, as the description therein has been updated and superseded by the description of the registrant’s capital stock contained in Exhibit 4.2 to the registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as filed with the Commission on February 23, 2023, and including any amendments and reports filed for the purpose of updating such description.

    All documents subsequently filed by the registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this registration statement and to be part hereof from the date of the filing of such documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this registration statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.

    Item 4. Description of Securities.

    Not applicable.


    Item 5. Interests of Named Experts and Counsel.

    Not applicable.

    Item 6. Indemnification of Directors and Officers.

    Section 145 of the General Corporation Law of the State of Delaware (“DGCL”) provides, generally, that a corporation shall have the power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding (except actions by or in the right of the corporation) by reason of the fact that such person is or was a director, officer, employee or agent of the corporation against all expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful. A corporation may similarly indemnify such person for expenses actually and reasonably incurred by such person in connection with the defense or settlement of any action or suit by or in the right of the corporation, provided that such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, in the case of claims, issues and matters as to which such person shall have been adjudged liable to the corporation, provided that a court shall have determined, upon application, that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which such court shall deem proper.

    Section 102(b)(7) of the DGCL provides, generally, that the registrant’s certificate of incorporation may contain a provision eliminating or limiting the personal liability of a director to the corporation or its shareholders for monetary damages for breach of fiduciary duty as a director, provided that such provision may not eliminate or limit the liability of a director (i) for any breach of the director’s duty of loyalty to the corporation or its shareholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) under section 174 of the DGCL, or (iv) for any transaction from which the director derived an improper personal benefit. No such provision may eliminate or limit the liability of a director for any act or omission occurring prior to the date when such provision became effective.

    The registrant’s certificate of incorporation provides that the registrant will indemnify each person who was or is a party or threatened to be made a party to any threatened, pending or completed action, suit or proceeding (other than an action by or in the right of the registrant) by reason of the fact that he or she is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at the registrant’s request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (all such persons being referred to as an “Indemnitee”), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys’ fees), liabilities, losses, judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding and any appeal therefrom, if such Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, the registrant’s best interests, and, with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful. The registrant’s certificate of incorporation provides that the registrant will indemnify any Indemnitee who was or is a party or threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the registrant to procure a judgment in its favor by reason of the fact that the Indemnitee is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at its request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise, or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys’ fees) and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding, and any appeal therefrom, if the Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, the registrant’s best interests, except that no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the registrant, unless a court determines that, despite such adjudication but in view of all of the circumstances, he or she is entitled to indemnification of such expenses. Notwithstanding the foregoing, to the extent that any Indemnitee has been successful, on the merits or otherwise, he or she will be indemnified by the registrant against all expenses (including attorneys’ fees) actually and reasonably incurred in connection therewith. Expenses must be advanced to an Indemnitee under certain circumstances.


    The registrant has entered into indemnification agreements with each of its directors and executive officers. These indemnification agreements may require the registrant, among other things, to indemnify its directors and officers for some expenses, including attorneys’ fees, judgments, fines and settlement amounts incurred by a director or officer in any action or proceeding arising out of his or her service as one of its directors or officers, or any of its subsidiaries or any other company or enterprise to which the person provides services at its request.

    The registrant maintains a general liability insurance policy that covers certain liabilities of directors and officers of the corporation arising out of claims based on acts or omissions in their capacities as directors or officers.

    Item 7. Exemption from Registration Claimed.

    Not applicable.

    Item 8. Exhibits.

     

    Exhibit
    Number
      

    Description of Exhibit

       Incorporated by Reference
       Form    File Number    Date of Filing    Exhibit
    Number
       Filed
    Herewith
     4.1    Restated Certificate of Incorporation of the Registrant    8-K    001-36014    July 30, 2013    3.1   
     4.2    Third Amended and Restated By-Laws of the Registrant    8-K    001-36014    March 23, 2023    3.1   
     5.1    Opinion of Wilmer Cutler Pickering Hale and Dorr LLP, counsel to the Registrant                X
    23.1    Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1)                X
    23.2    Consent of PricewaterhouseCoopers LLP, an independent registered public accounting firm                X
    24.1    Power of attorney (included on the signature pages of this registration statement)                X
    99.1    Form of Inducement Stock Option Agreement                X
    99.2    Form of Inducement Restricted Stock Unit Agreement                X
    99.3+    Form of Inducement Performance Stock Unit Agreement                X
    107    Calculation of Filing Fee Tables                X

     

    +

    Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.


    Item 9. Undertakings.

    1. Item 512(a) of Regulation S-K. The undersigned registrant hereby undertakes:

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

    provided, however, that paragraphs (1)(i) and (ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the registration statement.

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    2. Item 512(b) of Regulation S-K. The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    3. Item 512(h) of Regulation S-K. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on this 5th day of March, 2025.

     

    AGIOS PHARMACEUTICALS, INC.
    By:  

    /s/ Brian Goff

      Brian Goff
      Chief Executive Officer

    POWER OF ATTORNEY AND SIGNATURES

    We, the undersigned officers and directors of Agios Pharmaceuticals, Inc., hereby severally constitute and appoint Brian Goff, Cecilia Jones and James Burns, and each of them singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names in the capacities indicated below, the registration statement on Form S-8 filed herewith and any and all subsequent amendments to said registration statement, and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable Agios Pharmaceuticals, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments thereto.

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

      

    Title

     

    Date

    /s/ Brian Goff

    Brian Goff

      

    Chief Executive Officer and Director

    (Principal executive officer)

      March 5, 2025

    /s/ Cecilia Jones

    Cecilia Jones

      

    Chief Financial Officer

    (Principal financial officer)

      March 5, 2025

    /s/ T.J. Washburn

    T.J. Washburn

      

    Vice President, Controller

    (Principal accounting officer)

      March 5, 2025

    /s/ Jacqualyn A. Fouse

    Jacqualyn A. Fouse

       Chair of the Board of Directors   March 5, 2025

    /s/ Rahul Ballal

    Rahul Ballal, Ph.D.

       Director   March 5, 2025

    /s/ Jeffrey Capello

    Jeffrey Capello

       Director   March 5, 2025

    /s/ Kaye Foster

    Kaye Foster

       Director   March 5, 2025

    /s/ Maykin Ho

    Maykin Ho, Ph.D.

       Director   March 5, 2025


    /s/ Catherine Owen

    Catherine Owen

       Director   March 5, 2025

    /s/ David Scadden

    David Scadden, M.D.

       Director   March 5, 2025

    /s/ Cynthia Smith

    Cynthia Smith

       Director   March 5, 2025
    Get the next $AGIO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AGIO

    DatePrice TargetRatingAnalyst
    2/24/2025$58.00Buy
    H.C. Wainwright
    10/16/2024Sector Outperform
    Scotiabank
    10/10/2024$51.00Outperform
    Raymond James
    9/27/2024$60.00 → $56.00Outperform → Market Perform
    Leerink Partners
    2/8/2024Overweight
    Cantor Fitzgerald
    2/3/2023$41.00Overweight
    Piper Sandler
    11/17/2022$17.00 → $32.00Sell → Neutral
    Goldman
    7/27/2022$33.00Mkt Perform → Outperform
    SVB Leerink
    More analyst ratings

    $AGIO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025

      CAMBRIDGE, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the 2025 RBC Capital Markets Global Healthcare Conference on Wednesday, May 21, 2025, at 8:00 am ET. The live webcast will be accessible on the Investors section of the company's website (www.agios.com) under the "Events & Presentations" tab. A replay of the webcast will be archived on the company's website for at least two weeks following the presentation. About AgiosAgios is the pioneering leader in PK activation and is dedicated to devel

      5/9/25 7:00:00 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025

      CAMBRIDGE, Mass., May 02, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the BofA Securities 2025 Health Care Conference on Wednesday, May 14, 2025, at 8:00 am PT/11:00 am ET. The live webcast will be accessible on the Investors section of the company's website (www.agios.com) under the "Events & Presentations" tab. A replay of the webcast will be archived on the company's website for at least two weeks following the presentation. About AgiosAgios is the pioneering leader in PK activation and is dedicated to dev

      5/2/25 7:00:00 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights

      – U.S. Regulatory Filing Under Active Review for Approval of PYRUKYND® (mitapivat) in Thalassemia, with PDUFA Goal Date of September 7, 2025 – – Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease On Track, with Topline Results Expected in Late 2025; Potential U.S. Commercial Launch in 2026 – – Tebapivat Advancing in Clinical Trials for Lower-Risk Myelodysplastic Syndromes (LR-MDS) and Sickle Cell Disease – – PYRUKYND Net Revenue of $8.7 Million in Q1; Cash, Cash Equivalents and Marketable Securities of $1.4 Billion as of March 31, 2025 – CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and pyruvate kin

      5/1/25 6:30:00 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AGIO
    SEC Filings

    See more
    • SEC Form 10-Q filed by Agios Pharmaceuticals Inc.

      10-Q - AGIOS PHARMACEUTICALS, INC. (0001439222) (Filer)

      5/1/25 10:26:14 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Agios Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - AGIOS PHARMACEUTICALS, INC. (0001439222) (Filer)

      5/1/25 6:32:25 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Agios Pharmaceuticals Inc.

      DEFA14A - AGIOS PHARMACEUTICALS, INC. (0001439222) (Filer)

      4/25/25 4:05:10 PM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AGIO
    Financials

    Live finance-specific insights

    See more
    • Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights

      – U.S. Regulatory Filing Under Active Review for Approval of PYRUKYND® (mitapivat) in Thalassemia, with PDUFA Goal Date of September 7, 2025 – – Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease On Track, with Topline Results Expected in Late 2025; Potential U.S. Commercial Launch in 2026 – – Tebapivat Advancing in Clinical Trials for Lower-Risk Myelodysplastic Syndromes (LR-MDS) and Sickle Cell Disease – – PYRUKYND Net Revenue of $8.7 Million in Q1; Cash, Cash Equivalents and Marketable Securities of $1.4 Billion as of March 31, 2025 – CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and pyruvate kin

      5/1/25 6:30:00 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025

      CAMBRIDGE, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, May 1, 2025, at 8:00 a.m. ET to report its first quarter 2025 financial results and business highlights. The live webcast will be accessible on the Investors section of the company's website (www.agios.com) under the "Events & Presentations" tab. A replay of the webcast will be available on the company's website approximately two hours after the event. About AgiosAgios is the pioneering leader in PK act

      4/17/25 7:00:00 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

      – Filed for Regulatory Approval of Mitapivat (PYRUKYND®) for the Treatment of Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia in U.S., European Union, Kingdom of Saudi Arabia and United Arab Emirates; PDUFA Goal Date of September 7, 2025 – – Completed Enrollment for Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease; Topline Results Expected in Late 2025, with Potential U.S. Commercial Launch in 2026 – – Early- and Mid-Stage Pipeline Offers Strong Foundation for Innovation and Growth – – PYRUKYND Net Revenue of $10.7 Million in Q4; Cash, Cash Equivalents and Marketable Securitie

      2/13/25 6:31:00 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AGIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Agios Pharma with a new price target

      H.C. Wainwright initiated coverage of Agios Pharma with a rating of Buy and set a new price target of $58.00

      2/24/25 7:01:42 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scotiabank initiated coverage on Agios Pharma

      Scotiabank initiated coverage of Agios Pharma with a rating of Sector Outperform

      10/16/24 8:38:23 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Raymond James resumed coverage on Agios Pharma with a new price target

      Raymond James resumed coverage of Agios Pharma with a rating of Outperform and set a new price target of $51.00

      10/10/24 8:30:27 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AGIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Agios Pharmaceuticals Inc.

      SC 13G/A - AGIOS PHARMACEUTICALS, INC. (0001439222) (Subject)

      11/14/24 3:44:53 PM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Agios Pharmaceuticals Inc.

      SC 13G/A - AGIOS PHARMACEUTICALS, INC. (0001439222) (Subject)

      11/8/24 2:40:47 PM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Agios Pharmaceuticals Inc. (Amendment)

      SC 13G/A - AGIOS PHARMACEUTICALS, INC. (0001439222) (Subject)

      2/14/24 2:21:13 PM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AGIO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for PYRUKYND issued to AGIOS PHARMACEUTICALS INC

      Submission status for AGIOS PHARMACEUTICALS INC's drug PYRUKYND (ORIG-1) with active ingredient MITAPIVAT has changed to 'Approval' on 02/17/2022. Application Category: NDA, Application Number: 216196, Application Classification: Type 1 - New Molecular Entity

      2/17/22 2:39:08 PM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for TIBSOVO issued to AGIOS PHARMS INC

      Submission status for AGIOS PHARMS INC's drug TIBSOVO (SUPPL-7) with active ingredient IVOSIDENIB has changed to 'Approval' on 03/18/2021. Application Category: NDA, Application Number: 211192, Application Classification: Labeling

      3/22/21 5:06:31 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AGIO
    Leadership Updates

    Live Leadership Updates

    See more
    • Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer

      Cardurion Pharmaceuticals, Inc. ("Cardurion"), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of cardiovascular diseases, today announced that Charlotte (Charlie) Newman has joined the company as Chief Business Officer. A biopharmaceutical industry executive with over 25 years of industry experience, Ms. Newman most recently led corporate, portfolio and program strategy and business development as Chief Business Officer of Agios Pharmaceuticals (NASDAQ:AGIO), and previously held strategic product and portfolio roles at Biogen (NASDAQ:BIIB). In her role at Cardurion, she will be responsible for leading corporate development, bus

      1/8/25 8:00:00 AM ET
      $AGIO
      $BIIB
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Agios Appoints Catherine Owen to Board of Directors

      – John Maraganore Completes Tenure on Agios Board After Nearly a Dozen Years of Service – – Kaye Foster to Be Appointed Lead Independent Director – CAMBRIDGE, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that Catherine Owen has been appointed to its board of directors, effective June 13, 2023. Agios also announced that, following a collaborative succession planning process, John Maraganore, Ph.D., who has served as a valuable board member and advisor to the company since 2011, will step down from the board of directors, effective immediately, and

      5/25/23 7:00:00 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Agios Appoints Jeffrey Capello to Board of Directors

      – Board Member Paul Clancy Will Step Down at the End of His Term – CAMBRIDGE, Mass., April 19, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that Jeffrey Capello has been appointed to its board of directors. Agios also announced that Paul Clancy will step down from the board of directors at the end of his term, effective June 13, 2023. "Agios is dedicated to cultivating a diverse board that is focused on the company's long-term value creation for patients and shareholders. As such, we are thrilled to welcome Jeff, whose nearly 30-year track record of driving profitab

      4/19/23 7:00:00 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AGIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Fouse Jacqualyn A converted options into 15,933 shares and sold $194,172 worth of shares (7,497 units at $25.90), increasing direct ownership by 6% to 149,220 units (SEC Form 4)

      4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)

      4/10/25 4:02:58 PM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Corp Dev & Strategy Viswanadhan Krishnan

      4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)

      3/7/25 4:18:52 PM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Viswanadhan Krishnan

      3 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)

      3/7/25 4:15:46 PM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care